Literature DB >> 21575037

Population diversity and the performance of warfarin dosing algorithms.

Guilherme Suarez-Kurtz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21575037      PMCID： PMC3175514          DOI： 10.1111/j.1365-2125.2011.04018.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

1.  Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose.

Authors:  Guilherme Suarez-Kurtz; Jamila A Perini; Edimilson Silva-Assunção; Claudio J Struchiner
Journal:  Blood       Date:  2009-04-23       Impact factor: 22.113

2.  Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.

Authors:  J A Perini; C J Struchiner; E Silva-Assunção; I S C Santana; F Rangel; E B Ojopi; E Dias-Neto; G Suarez-Kurtz
Journal:  Clin Pharmacol Ther       Date:  2008-08-27       Impact factor: 6.875

3.  Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients.

Authors:  E Hatch; H Wynne; P Avery; M Wadelius; F Kamali
Journal:  J Thromb Haemost       Date:  2008-04-14       Impact factor: 5.824

4.  Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.

Authors:  Nita A Limdi; Mia Wadelius; Larisa Cavallari; Niclas Eriksson; Dana C Crawford; Ming-Ta M Lee; Chien-Hsiun Chen; Alison Motsinger-Reif; Hersh Sagreiya; Nianjun Liu; Alan H B Wu; Brian F Gage; Andrea Jorgensen; Munir Pirmohamed; Jae-Gook Shin; Guilherme Suarez-Kurtz; Stephen E Kimmel; Julie A Johnson; Teri E Klein; Michael J Wagner
Journal:  Blood       Date:  2010-03-04       Impact factor: 22.113

5.  A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

Authors:  D Voora; D C Koboldt; C R King; P A Lenzini; C S Eby; R Porche-Sorbet; E Deych; M Crankshaw; P E Milligan; H L McLeod; S R Patel; L H Cavallari; P M Ridker; G R Grice; R D Miller; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-03-03       Impact factor: 6.875

6.  CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Authors:  Stuart A Scott; Malgorzata Jaremko; Steven A Lubitz; Ruth Kornreich; Jonathan L Halperin; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

7.  Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.

Authors:  Mariana Rodrigues Botton; Eliane Bandinelli; Luis Eduardo Paim Rohde; Luis Carlos Amon; Mara Helena Hutz
Journal:  Br J Clin Pharmacol       Date:  2011-09       Impact factor: 4.335

8.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

Authors:  Elizabeth A Sconce; Tayyaba I Khan; Hilary A Wynne; Peter Avery; Louise Monkhouse; Barry P King; Peter Wood; Patrick Kesteven; Ann K Daly; Farhad Kamali
Journal:  Blood       Date:  2005-06-09       Impact factor: 22.113

9.  Race and ancestry in biomedical research: exploring the challenges.

Authors:  Timothy Caulfield; Stephanie M Fullerton; Sarah E Ali-Khan; Laura Arbour; Esteban G Burchard; Richard S Cooper; Billie-Jo Hardy; Simrat Harry; Robyn Hyde-Lay; Jonathan Kahn; Rick Kittles; Barbara A Koenig; Sandra Sj Lee; Michael Malinowski; Vardit Ravitsky; Pamela Sankar; Stephen W Scherer; Béatrice Séguin; Darren Shickle; Guilherme Suarez-Kurtz; Abdallah S Daar
Journal:  Genome Med       Date:  2009-01-21       Impact factor: 11.117

10.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245
View more
  10 in total

1.  Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study.

Authors:  Vanessa Cristina de Oliveira Almeida; Daniel Dias Ribeiro; Karina Braga Gomes; Ana Lúcia Brunialti Godard
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

2.  Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.

Authors:  Mennat-Allah Kamal El-Din; Marwa Salah Farhan; Randa Ibrahim El Shiha; Rania Mohammed Helmy El-Kaffas; Somaia Mohammed Mousa
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

3.  Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction.

Authors:  Daniel Kurnik; Husam Qasim; Sophie Sominsky; Aharon Lubetsky; Noa Markovits; Chun Li; C Michael Stein; Hillel Halkin; Eva Gak; Ronen Loebstein
Journal:  Thromb Haemost       Date:  2012-08-07       Impact factor: 5.249

Review 4.  Pharmacogenomics of warfarin in populations of African descent.

Authors:  Guilherme Suarez-Kurtz; Mariana R Botton
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

5.  Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals.

Authors:  Maryam H Alrashid; Ahmad Al-Serri; Salem H Alshemmari; Philip Koshi; Suzanne A Al-Bustan
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

6.  Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.

Authors:  Cristina Mazzaccara; Valeria Conti; Rosario Liguori; Vittorio Simeon; Mario Toriello; Angelo Severini; Corrado Perricone; Alfonso Meccariello; Pasquale Meccariello; Dino Franco Vitale; Amelia Filippelli; Lucia Sacchetti
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

7.  Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations.

Authors:  Vania Bonifaz-Peña; Alejandra V Contreras; Claudio Jose Struchiner; Rosimeire A Roela; Tatiane K Furuya-Mazzotti; Roger Chammas; Claudia Rangel-Escareño; Laura Uribe-Figueroa; María José Gómez-Vázquez; Howard L McLeod; Alfredo Hidalgo-Miranda; Esteban J Parra; Juan Carlos Fernández-López; Guilherme Suarez-Kurtz
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

8.  Evaluation of the anticoagulant effect and timing of the concomitant use of S-1 and warfarin.

Authors:  Shinya Suzuki; Kiwako Ikegawa; Kaori Yamamoto; Shinichiro Saito
Journal:  J Int Med Res       Date:  2016-09-27       Impact factor: 1.671

9.  Creating and validating a warfarin pharmacogenetic dosing algorithm for Colombian patients.

Authors:  Jubby Marcela Galvez; Carlos Martin Restrepo; Nora Constanza Contreras; Clara Alvarado; Carlos-Alberto Calderón-Ospina; Nidia Peña; Ricardo A Cifuentes; Daniela Duarte; Paul Laissue; Dora Janeth Fonseca
Journal:  Pharmgenomics Pers Med       Date:  2018-10-16

10.  Genetic Variation of G6PD and CYP2D6: Clinical Implications on the Use of Primaquine for Elimination of Plasmodium vivax.

Authors:  Alexandra G A Stewart; Peter A Zimmerman; James S McCarthy
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.